Loading...
XJPX
4575
Market cap94mUSD
Oct 09, Last price  
801.00JPY
1D
5.53%
1Q
5.67%
Jan 2017
31.74%
IPO
-77.44%
Name

CanBas Co Ltd

Chart & performance

D1W1MN
XJPX:4575 chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
21.04%
Rev. gr., 5y
10.34%
Revenues
0
56,000,000170,178,000161,765,000148,335,000000060,958,000105,243,000109,852,000110,000,000115,550,000110,000,000108,945,00000000
Net income
-1.31b
L+13.12%
-420,000,000-125,376,000-222,675,00053,378,000-1,501,513,000-1,119,584,000-643,000,000-376,000,000-266,964,000-414,989,000-419,498,000-532,087,000-456,208,000-572,790,000-531,034,000-855,577,000-1,244,108,000-1,209,000,000-1,157,000,000-1,308,808,000
CFO
-1.42b
L+84.59%
-552,921,000-688,572,000-719,814,000-1,398,936,000-1,280,192,000-771,454,000-1,424,000,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating various cancers, and CBS9106, a reversible exportin-1 inhibitor currently in Phase I clinical trials for solid tumors. The company also engages in a strategic partnership with Stemline Therapeutics, Inc. Established in Numazu, Japan, in 2000, CanBas Co., Ltd. continues its work in oncology.

Key people

Takumi Kawabe
President, Representative Director · since 2003
Makoto Katozumi
Chief Financial Officer, Manager of Business Planning Office, Director · since 2020
Kazuyoshi Sakamoto
Director of Administration, Director · since 2020
Toshiyuki Hibino
Chief Operating Officer, Director of Research Development, Director · since 2021
Toshio Furuta
Independent Director · since 2016
Yasuyuki Komiyama
Independent Director · since 2016
Akio Shirakawa
Independent Director · since 2016
URL
https://www.canbas.co.jp/
IPO date
Sep 17, 2009
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT